• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Phys Chem Chem Phys . Selectivity mechanism of the PB2 cap-binding domain of influenza A and B viruses for methylated cap analogs: insights from MD

tetano

Editor, Senior Moderator
Phys Chem Chem Phys


. 2025 Sep 25.
doi: 10.1039/d5cp01778e. Online ahead of print. Selectivity mechanism of the PB2 cap-binding domain of influenza A and B viruses for methylated cap analogs: insights from MD simulations

Ye Xiao[SUP] 1 [/SUP], Jilong Zhang[SUP] 1 [/SUP], Ran Jia[SUP] 1 [/SUP]



Affiliations
Abstract

The PB2 cap-binding domain (PB2[SUB]cap[/SUB]) of the influenza virus is considered an important target for blocking viral transcription due to its cap binding. The lack of the complex structures of PB2[SUB]cap[/SUB] with m[SUP]7[/SUP]GDP limits the exploration of the binding differences between the PB2[SUB]cap[/SUB] of influenza A and B viruses (FluA and FluB, respectively) with methylated cap analogs (m[SUP]7[/SUP]GTP and m[SUP]7[/SUP]GDP). In this study, based on the complex structures of FluA-D and FluB-D obtained using Discovery Studio 2.5 software and the crystal structures of FluA and FluB with m[SUP]7[/SUP]GTP (FluA-T and FluB-T), we investigated the binding of FluA and FluB with m[SUP]7[/SUP]GTP and m[SUP]7[/SUP]GDP by molecular dynamics simulations and MM-GBSA calculations. The results show that m[SUP]7[/SUP]GTP binding affinity is greater than that of m[SUP]7[/SUP]GDP for FluA and FluB, with a more pronounced affinity for FluA than that for FluB. The differences in the properties of the key residues of FluA (F323, H357 and N429) and FluB (Q325, W359 and S431) and the structures of the methylated cap analogs may explain the differences in binding abilities. Besides, the sandwich structure, π-π stacking interactions, and the electrostatic interactions between PB2[SUB]cap[/SUB] and methylated cap analogs are the key factors in stabilizing the positioning in the binding pockets. Our work could provide some valuable theoretical clues for the development of influenza virus PB2 inhibitors.


 
Back
Top